Sutro Biopharma, Inc. (STRO) — 10-Q Filings
All 10-Q filings from Sutro Biopharma, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Sutro Biopharma's Losses Mount Amid Deep Restructuring, Nasdaq Threat
— Nov 6, 2025 Risk: high
Sutro Biopharma, Inc. reported a net loss of $56.857 million for the three months ended September 30, 2025, an increase from $48.787 million in the same period -
Sutro Biopharma's Q2 Loss Widens to $58.1M Amid Revenue Dip
— Aug 7, 2025 Risk: high
Sutro Biopharma, Inc. reported a net loss of $58.1 million for the three months ended June 30, 2025, a significant increase from the $49.5 million net loss for -
Sutro Biopharma Files 10-Q, Mentions Astellas Deal
— May 8, 2025 Risk: medium
Sutro Biopharma, Inc. filed its 10-Q for the period ending March 31, 2025. The company's business address is 111 Oyster Point Blvd., South San Francisco, CA. Ke -
Sutro Biopharma Files Q3 2024 10-Q
— Nov 13, 2024 Risk: medium
Sutro Biopharma, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial condition and business operations, includin -
Sutro Biopharma R&D Surges in Q2 2024
— Aug 13, 2024 Risk: medium
Sutro Biopharma, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported research and development expenses of $75.6 million for the six mo -
Sutro Biopharma, Inc. Files 10-Q for Period Ending March 31, 2024
— May 13, 2024 Risk: medium
SUTRO BIOPHARMA, INC. (STRO) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Sutro Biopharma, Inc. reported its financial results for the quarter
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX